Have a feature idea you'd love to see implemented?
Let us know!
DYN Dyne Therapeutics Inc
Price (delayed)
$29.73
Market cap
$3.03B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.56
Enterprise value
$2.52B
Dyne Therapeutics, Inc. operates as a biotechnology company. The Company focuses on transforming the lives of people with serious diseases by developing muscle-targeted therapies. Dyne Therapeutics offers its services in
Highlights
The debt is down by 12% year-on-year and by 3.3% since the previous quarter
DYN's net income is down by 42% YoY and by 14% QoQ
Dyne Therapeutics's quick ratio has decreased by 36% from the previous quarter
Key stats
What are the main financial stats of DYN
Market
Valuations
Earnings
Shares outstanding
101.77M
Market cap
$3.03B
Enterprise value
$2.52B
Price to earnings (P/E)
N/A
Price to book (P/B)
4.23
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$294.51M
EBITDA
-$292.29M
Free cash flow
-$244.42M
Per share
Balance sheet
Liquidity
EPS
-$3.56
Free cash flow per share
-$2.42
Book value per share
$7.03
Revenue per share
$0
TBVPS
$7.62
Total assets
$768.84M
Total liabilities
$63.3M
Debt
$24.86M
Equity
$705.54M
Working capital
$693.13M
Debt to equity
0.04
Current ratio
17.02
Quick ratio
16.77
Net debt/EBITDA
1.74
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-51.6%
Return on equity
-57.5%
Return on invested capital
-168.8%
Return on capital employed
-40.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
DYN stock price
How has the Dyne Therapeutics stock price performed over time
Intraday
-0.87%
1 week
-1.91%
1 month
-11.2%
1 year
182.87%
YTD
123.53%
QTD
-17.23%
Financial performance
How have Dyne Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$314.47M
Net income
-$294.51M
Gross margin
N/A
Net margin
N/A
DYN's operating income is down by 47% YoY and by 16% QoQ
DYN's net income is down by 42% YoY and by 14% QoQ
Growth
What is Dyne Therapeutics's growth rate over time
Valuation
What is Dyne Therapeutics stock price valuation
P/E
N/A
P/B
4.23
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The price to book (P/B) is 36% higher than the 5-year quarterly average of 3.1 but 26% lower than the last 4 quarters average of 5.7
The equity has contracted by 9% from the previous quarter
Efficiency
How efficient is Dyne Therapeutics business performance
The return on equity is up by 41% year-on-year and by 17% since the previous quarter
The company's return on assets rose by 35% YoY and by 14% QoQ
DYN's return on invested capital is up by 17% year-on-year and by 9% since the previous quarter
Dividends
What is DYN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for DYN.
Financial health
How did Dyne Therapeutics financials performed over time
Dyne Therapeutics's current ratio has decreased by 36% from the previous quarter
Dyne Therapeutics's quick ratio has decreased by 36% from the previous quarter
The debt is 96% smaller than the equity
Dyne Therapeutics's debt to equity has shrunk by 79% YoY but it has increased by 33% QoQ
The debt is down by 12% year-on-year and by 3.3% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.